Dashboard
Manage Tickers

KALV


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
09/06/2024 11:39:58

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.

kalvista-presented-additional-analyses-of-efficacy-and-safety-of-sebetralstat-from-phase-2-and-phase-3-double-blind-placebo-controlled-crossover-clinical-trials-as-well-as-interim-data-from-konfident-s--a-phase-3-open-label-extension-trial
KalVista Presented Additional Analyses Of ...
09/06/2024 10:35:41

Data was presented at the Bradykinin Symposium 2024 taking place in Berlin, Germany, on September 5-6. Sebetralstat is a novel,...

needham-reiterates-buy-on-kalvista-pharma-maintains-32-price-target
Needham Reiterates Buy on KalVista Pharma,...
09/06/2024 09:32:41

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $32 price target.

kalvista-pharma-q1-2025-gaap-eps-087-beats-091-estimate-cash-balance-of-1743m
KalVista Pharma Q1 2025 GAAP EPS $(0.87) B...
09/05/2024 10:34:58

kalvistas-sebetralstat-nda-accepted-by-fda-could-be-first-oral-on-demand-hae-treatment-by-mid-2025
KalVista's Sebetralstat NDA Accepted by FD...
09/03/2024 10:32:28

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the U.S. Food and Drug Administration (FDA) has accepted its...

the-european-medicines-agency-has-validated-the-submission-of-kalvista-pharmaceuticals-marketing-application-seeking-approval-for-sebetralstat-for-the-on-demand-treatment-of-hereditary-angioedema
The European Medicines Agency Has Validate...
08/15/2024 10:35:24

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
07/15/2024 10:42:20

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.

nvidia-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-friday
NVIDIA To Rally More Than 33%? Here Are 10...
07/12/2024 13:01:36

needham-maintains-buy-on-kalvista-pharma-lowers-price-target-to-32
Needham Maintains Buy on KalVista Pharma, ...
07/12/2024 09:37:24

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $35 to $32.

kalvista-submits-fda-application-for-sebetralstat-phase-3-trial-results-published
KalVista Submits FDA Application for Sebet...
07/11/2024 10:37:03

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fisca...

kalvista-pharma-q4-eps-102-misses-073-estimate-cash-balance-of-2104m
KalVista Pharma Q4 EPS $(1.02) Misses $(0....
07/11/2024 10:35:02

kalvista-pharmaceuticals-has-initiated-open-label-konfident-kid-trial-of-sebetralstat-in-pediatric-patients-with-hereditary-angioedema-the-trial-will-enroll-approximately-24-children-aged-2-to-11-years
KalVista Pharmaceuticals Has Initiated Ope...
06/27/2024 10:37:39

If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the secon...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
06/18/2024 14:45:59

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-submits-new-drug-application-for-fda-review-of-sebetralstat
KalVista Submits New Drug Application For ...
06/18/2024 10:32:18

Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (...

kalvista-pharmaceuticals-presented-us-subgroup-analysis-from-sebetralstat-phase-3-konfident-trial-real-world-claims-and-patient-survey-data-at-eastern-allergy-conference-2024-and-japanese-subgroup-at-annual-meeting-of-japanese-dermatological-association
KalVista Pharmaceuticals Presented US Subg...
06/06/2024 10:35:57

kalvista-highlights-real-world-data-on-hae-treatments-and-patient-experiences-at-eaaci-congress
KalVista Highlights Real-World Data on HAE...
06/03/2024 10:36:32

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that as...

kalvista-pharmaceuticals-presents-late-breaking-phase-3-konfident-trial-data-on-sebetralstat-at-eaaci-congress-nejm-publication-highlights-9-minute-median-time-to-treatment-and-13-hour-symptom-relief-for-laryngeal-attacks-in-konfident-s-trial
KalVista Pharmaceuticals Presents Late-Bre...
05/31/2024 16:17:25

kalvista-pharmaceuticals-says-that-ten-abstracts-accepted-for-presentation-at-the-european-academy-of-allergy-and-clinical-immunology-congress-2024
KalVista Pharmaceuticals Says That Ten Abs...
05/24/2024 10:32:32

The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 is taking place in Valencia, Spain from May 31-Ju...

hc-wainwright--co-maintains-buy-on-kalvista-pharma-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on KalVi...
05/03/2024 19:44:50

HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target f...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
05/01/2024 16:14:49

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION